Ovid Therapeutics announced the departure of Thomas Perone, the former General Counsel, Chief Compliance Officer, and Corporate Secretary, effective July 11, 2024, due to a workforce reduction. However, the company entered into a consulting services agreement with Mr. Perone, where he will continue to consult for the company until January 31, 2025, and receive a monthly consulting fee and vesting of equity awards.